HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Barker, M. Articles by Koppmann, R. Search for Related Content PubMed PubMed Citation Articles by Barker, M. Articles by Koppmann, R.

Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis

¹ Dept of Paediatrics, University of Technology (RWTH) Medical Center, Aachen, ² Institute of Chemistry and Dynamics of the Geosphere, Division II, Troposphere, and ³ Central Library, Research Center Jülich, Jülich, Germany.

CORRESPONDENCE: M. Barker, Kinderklinik, Universitätsklinikum Aachen, Pauwelsstr. 30, 52074 Aachen, Germany. Fax: 49 2418082599. E-mail: Barker{at}rwth-aachen.de

Keywords: Biological markers, breath tests, cystic fibrosis, gas chromatography

Received: July 21, 2005
Accepted January 24, 2006

Inflammatory mediators in the exhaled breath are receiving growing medical interest as noninvasive disease markers. Volatile organic compounds have been investigated in this context, but clinical information and methodological standards are limited.

The levels of ethane, propane, n-pentane, methanol, ethanol, 2-propanol, acetone, isoprene, benzene, toluene, dimethyl sulphide (DMS) and limonene were measured in repeated breath samples from 20 cystic fibrosis patients and 20 healthy controls (aged 8–29 yrs). Three end-exhaled and one ambient air sample were collected per person and analysed on a customised gas chromatography system.

Intra-subject coefficients of variation ranged between 9 and 34%, and hydrocarbon breath levels were influenced by their inspired concentrations. The alveolar gradient for pentane was higher in cystic fibrosis patients than in healthy controls (0.36 versus 0.21 ppb) and inversely proportional to forced expiratory volume in one second; highest values were observed in patients with pulmonary exacerbations (0.73 versus 0.24 ppb). Cystic fibrosis patients also exhibited a lower output of DMS (3.9 versus 7.6 ppb). Group differences were not significant for ethane and the remaining substances.

It was concluded that chemical breath analysis for volatile organic compounds is feasible and may hold potential for the noninvasive diagnosis and follow-up of inflammatory processes in cystic fibrosis lung disease.